U.S. markets open in 1 hour 39 minutes

Aura Biosciences, Inc. (AURA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.21+1.08 (+10.66%)
At close: 04:00PM EST
11.21 0.00 (0.00%)
After hours: 04:01PM EST

Aura Biosciences, Inc.

85 Bolton Street
Cambridge, MA 02140
United States
617 500 8864

Full Time Employees52

Key Executives

NameTitlePayExercisedYear Born
Dr. Elisabet de los Pinos Ph.D.Founder, CEO, Pres & Director676.62kN/A1974
Ms. Julie B. FederCFO, Sec. & Treasurer505.45kN/A1970
Dr. Cadmus Collins Rich CPE, M.B.A., M.D., MBAChief Medical Officer and Head of R&D564.22kN/A1965
Dr. Mark A. De Rosch Ph.D.Chief Operating OfficerN/AN/A1964
Mr. Paulo CarvalhoVP of Technical OperationsN/AN/AN/A
Mr. Joseph LyonsVP of HRN/AN/AN/A
Ms. Michele Keough M.B.A.Sr. VP of Project Management and Device Supply ChainN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Aura Biosciences, Inc.’s ISS Governance QualityScore as of February 1, 2023 is 8. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.